Dr. Mendlein is an Executive Partner of Flagship Pioneering, a venture capital firm. Prior to joining Flagship, Dr. Mendlein served as President, Corporate and Product Strategy, of Moderna, Inc., a clinical stage biotechnology company. Dr. Mendlein was also a member of Moderna’s board of directors from 2012-2018. Dr. Mendlein has also held leadership roles at multiple biotech companies, including Chief Knowledge Officer and General Counsel at Aurora Biosciences (acquired by Vertex Pharmaceuticals) where he also served as a board member; CEO of Adnexus Therapeutics, a biopharmaceutical company acquired by BMS; and Executive Chairman and CEO of Affinium Pharmaceuticals (acquired by Debiopharm Group). He has served on the boards of the Biotechnology Innovation Organization (BIO), as well as Axcella Therapeutics and Editas Medicine. John currently serves on the boards of Omega Therapeutics, Empress, and Ampersand, and is Executive Chairman of Sail Biomedicines. Dr. Mendlein holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in biology from the University of Miami.